Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The company has applied for FDA approval of Symplicity Spyral, an experimental device used to perform a minimally invasive treatment procedure.

Medtronic Blood-Pressure Device Curbs Hypertension, but Misses Top Goal in Study

DUBLIN and CHICAGO , Nov. 7, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the six-month results from the full cohort of the SPYRAL HTN-ON MED clinical trial. The data were presented today as Late-Breaking Clinical Science at the American Heart Association (AHA) Scientific Sessions 2022.

SPYRAL HTN-ON MED study demonstrates meaningful clinical benefits consistent with other SPYRAL HTN renal denervation trials

New York, New York--(Newsfile Corp. - November 7, 2022) - Levi & Korsinsky, LLP notifies investors in Medtronic plc ("Medtronic" or the "Company") (NYSE: MDT) of a class action securities lawsuit.The lawsuit on behalf of Medtronic investors has been commenced in the the United States District Court for the District of Minnesota.

Medtronic Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before November 7, 2022 to Discuss Your Rights - MDT

Los Angeles, California--(Newsfile Corp. - November 7, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Medtronic plc ("Medtronic" or "the Company") (NYSE: MDT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Medtronic plc with Losses of $500,000 to Contact the Firm

NEW YORK , Nov. 7, 2022 /PRNewswire/ -- Attention Medtronic plc ("Medtronic") (NYSE: MDT) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors. This lawsuit is on behalf of persons and entities who purchased or otherwise acquired Medtronic common stock between June 8, 2019, and May 25, 2022, inclusive.

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Medtronic Investors of a Lead Plaintiff Deadline of November 7, 2022

New York, New York--(Newsfile Corp. - November 6, 2022) - Levi & Korsinsky, LLP notifies investors in Medtronic plc ("Medtronic" or the "Company") (NYSE: MDT) of a class action securities lawsuit.The lawsuit on behalf of Medtronic investors has been commenced in the the United States District Court for the District of Minnesota.

MDT LAWSUIT ALERT: Levi & Korsinsky Notifies Medtronic plc Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK , Nov. 4, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Medtronic plc (NYSE: MDT). To receive updates on the lawsuit, fill out the form: https://claimyourloss.com/securities/medtronic-plc-loss-submission-form/?id=33299&from=4 This lawsuit is on behalf of persons and entities who purchased or otherwise acquired Medtronic common stock between June 8, 2019, and May 25, 2022, inclusive.

MDT SHAREHOLDER ALERT: Jakubowitz Law Reminds Medtronic Shareholders of a Lead Plaintiff Deadline of November 7, 2022

Medtronic is getting ready to spin off a division, but it has made it very clear that dividend investors don't need to worry.

This Dividend Stock Is Breaking Up, but Income Investors Shouldn't Worry

CEDARHURST, N.Y. , Nov. 2, 2022 /PRNewswire/ -- The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of Medtronic plc (NYSE: MDT), if they purchased the Company's shares between June 8, 2019, and May 25, 2022, inclusive (the "Class Period").

FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Medtronic plc - MDT

Teladoc

Ontario Paramedic Service is the fifth County to choose Cloud DX Connected Health™ to improve positive patient outcomes as part of its Community Paramedicine Remote Monitoring program News in Summary As hospital-at-home and community remote monitoring programs increase in scale, Cloud DX expects to deploy over 1,000 Connected Health kits for this use case by early 2023. Paramedicine deployments are funded through the $82 million Community Paramedicine Long Term Care Program.

Cloud DX Announces 6th Ontario Paramedicine Group Contract

Enbridge

Essex Property Trust

Federal Realty Investment Trust

Stanley Black & Decker

The November 8th midterms are 81% likely to lead to divided government and a very healthy 12-month post-election rally. Stock returns are almost always independent on who controls the White House and Congress. "If you mix politics and investing, you're making a big mistake." - Warren Buffett.

Buy These 5 High-Yield Dividend Aristocrats Before The Election

NEW YORK , Nov. 2, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Medtronic plc. Shareholders who purchased shares of MDT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Medtronic plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 7, 2022 - (NYSE: MDT)

New York, New York--(Newsfile Corp. - November 1, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Medtronic Plc (""Medtronic" or the "Company") (NYSE: MDT). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Medtronic and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Medtronic Plc - MDT

New York, New York--(Newsfile Corp. - November 1, 2022) - Levi & Korsinsky, LLP notifies investors in Medtronic plc ("Medtronic" or the "Company") (NYSE: MDT) of a class action securities lawsuit.The lawsuit on behalf of Medtronic investors has been commenced in the the United States District Court for the District of Minnesota.

Medtronic Class Action: Levi & Korsinsky Reminds Medtronic plc Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 7, 2022 - MDT

NEW YORK , Nov. 1, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Medtronic plc (NYSE: MDT) alleging that the Company violated federal securities laws. This lawsuit is on behalf of persons and entities who purchased or otherwise acquired Medtronic common stock between June 8, 2019, and May 25, 2022, inclusive.Lead Plaintiff Deadline: November 7, 2022 No obligation or cost to you.

MDT ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of November 7, 2022 in the Class Action Filed on Behalf of Medtronic plc Shareholders

An upcoming buy-one-get-one-free deal could do wonders for your passive-income stream.

Does an Upcoming Spinoff Makes This Dividend-Paying Stock a Smart Buy Now?

NEW ORLEANS , Oct. 28, 2022 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until November 7, 2022 to file lead plaintiff applications in a securities class action lawsuit against Medtronic plc (NYSE: MDT), if they purchased the Company's shares between June 8, 2019, and May 25, 2022, inclusive (the "Class Period").

MEDTRONIC SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Medtronic plc - MDT

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the stock of Medtronic plc (NYSE: MDT) between June 8, 2019 and May 25, 2022, both dates inclusive (the “Class Period”), of the important November 7, 2022 lead plaintiff deadline.

ROSEN, A RANKED AND LEADING FIRM, Encourages Medtronic plc Investors to Secure Counsel Before Important November 7 Deadline in Securities Class Action – MDT

The medical device maker is looking to up its growth game by shedding two divisions. We take a look at the possible outcomes.

Medtronic Is Doing a Spinoff. The Fallout for Our Stock Pick.

Abbott Labs

Albemarle

Clorox

Ecolab

Lowe's

McCormick

Nucor

Realty Income Corp

Sherwin-Williams

Sysco

Target

T. Rowe Price Group

V.F.

Walgreens

West Pharmaceutical Services

NOBL fell 9.15% in September, which brings the Funds return for the year to a loss of 17.47%. Thus far this month, through October 24th, the dividend aristocrat ETF is up 6.04%, bringing its year-to-date return to -12.49%.

My Best Dividend Aristocrats For November 2022

New Medtronic Neurovascular Co-Lab™ Platform drives collaboration and connections among start-ups, physicians, and institutions; aims to improve stroke treatment and access for patients worldwide DUBLIN , Oct. 26, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the launch of Medtronic Neurovascular Co-Lab™ Platform designed to accelerate urgently needed innovation in stroke care and treatment. The company is harnessing its market-leading position and trusted partner reputation to create a platform that will ultimately advance technology concepts that have the highest potential to positively impact millions of stroke patients.

Announcing the launch of Medtronic Neurovascular Co-Lab™ Platform to accelerate innovation in stroke treatment

NEW YORK , Oct. 25, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the stock of Medtronic plc (NYSE: MDT) between June 8, 2019 and May 25, 2022, both dates inclusive (the "Class Period"), of the important November 7, 2022 lead plaintiff deadline. SO WHAT: If you purchased Medtronic securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LEADING LAW FIRM, Encourages Medtronic plc Investors With Losses to Secure Counsel Before Important November 7 Deadline in Securities Class Action - MDT

Elective and deferred surgeries booming during the Covid reopening fell short of projections. This has weighed down the healthcare equipment space. While many names in the space now have reasonable valuations, Medtronic is the most enticing for yield.

Medtronic: 45 Years Of Dividend Increases, All-Time High Yield

DUBLIN , Oct. 24, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the Chief Executives for Corporate Purpose's (CECP's) 10th CEO Investor Forum held at AdvaMed's 2022 MedTech Conference on Tuesday, October 25, 2022, in Boston, MA. Geoff Martha, Medtronic chairman and chief executive officer, will make a formal presentation and answer questions on the company beginning at 3:30 p.m.

Medtronic chairman and CEO Geoff Martha to speak at the CECP's CEO Investor Forum

The medical-technology and services company said both units, which are part of its medical surgical portfolio, generated revenue of about $2.2 billion in 2022.

News for Medtronic Stock (MDT)